Company Filing History:
1 out of 40 
1 out of 55 
1 out of 71 Years Active: 2025
Title: Innovations in Cardiac Fibrosis Treatment by Jean-Sébastien Hulot
Introduction
Jean-Sébastien Hulot is a prominent inventor based in Paris, France. He has made significant contributions to the field of cardiac health, particularly in understanding and treating cardiac fibrosis. His innovative work has the potential to improve clinical outcomes for patients suffering from myocardial infarction.
Latest Patents
Hulot holds a patent titled "Use of cilengitide for ameliorating cardiac fibrosis occurring in response to myocardial infarction." This patent addresses the role of activated cardiac fibroblasts in the production of extracellular matrix proteins that accumulate during cardiac fibrosis. The research identifies αV-integrin (or CD51) as a crucial regulator of PW1 cardiac adult stem cells' fibrogenic behavior. Inhibition of αV-integrin reduces profibrotic gene expression and the differentiation ability of cardiac PW1 cells into fibroblasts. The pharmacological blockade of αV-containing integrins has been shown to improve cardiac function and survival after myocardial infarction by reducing infarct size and limiting the extension of reactive cardiac fibrosis. Notably, the total cardiac fibrotic area and interstitial fibrosis in the remote myocardial area are significantly reduced following this pharmacological intervention. This research highlights a new mechanism regulating cardiac fibrosis in response to ischemic injury and suggests that targeting αV-integrin may offer clinical benefits in treating cardiac fibrosis.
Career Highlights
Hulot has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université Paris Cité. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Hulot's notable coworkers include Anne-Marie Lompre and Yassine Sassi. Their collaborative efforts have further advanced the understanding of cardiac health and the mechanisms underlying cardiac fibrosis.
Conclusion
Jean-Sébastien Hulot's innovative research and patent in the field of cardiac fibrosis represent a significant advancement in medical science. His work has the potential to transform treatment approaches for patients suffering from myocardial infarction and related conditions.